Boehringer’s approved ‘Jardiance Duo’ fuels competition among SGLT-2 complexes
In the SGLT-2-inhibitor antidiabetic treatment market led by AstraZeneca’s ‘Forxiga(dapagliflozin)’ by itself, competition is expected among complexes.
According to the industry concerned on the 22nd, ‘Jardiance Duo Tab,’ a Boehringer Ingelheim’s SGLT-2 inhibitor, is looking forward to its domes...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
